Apr 03, 2020
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
Mar 05, 2020
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class And Segment Forecasts, 2020 - 2027
Jan 15, 2020
Visiongain Publishes Global Pulmonary Arterial Hypertension Market 2019-2029 Report
Jan 09, 2020
Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Nov 12, 2019
Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH
Oct 30, 2019
Actimed Therapeutics Appoints Robin Bhattacherjee as CEO
Oct 21, 2019
New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension
Sep 27, 2019
Visiongain Report Looks at Opportunities Within the $23bn Hypertension Drugs Market
Aug 28, 2019
Niemann-Pick Disease Type C (NPC) Insights, Epidemiology, and Market Forecasts, 2028
Jun 26, 2019
Opsumit Drug Profile 2016-2025: Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) is Set to Become the Market Leader with Forecast Peak Sales of $2.2bn in 2025
May 29, 2019
The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026
May 20, 2019
New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early
Mar 26, 2019
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Jan 16, 2019
Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application
Sep 17, 2018
Blood Pressure Disorders Drug Development Pipeline Review 2018 - Molecule Type, Molecular Target, Mechanism of Action and Route of Administration
Jun 08, 2018
Fabry's Disease Pipeline Analysis 2018: Major Players are Actelion Pharmaceuticals, Sanofi, Amicus Therapeutics, Protalix and Shire
Apr 30, 2018
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Apr 10, 2018
Pulmonary Arterial Hypertension (PAH) Market Size Anticipated to Reach $8.7 Billion by 2025 | Million Insights
Feb 07, 2018
PharmaBoardroom Releases 'Healthcare and Life Sciences Review Switzerland 2018'
Dec 15, 2017
Global Anti-idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027